Literature DB >> 21747169

Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives β-catenin/T cell factor-dependent hepatocarcinogenesis.

Hai Feng1, Alfred S L Cheng, Daisy P Tsang, May S Li, Minnie Y Go, Yue S Cheung, Gui-jun Zhao, Samuel S Ng, Marie C Lin, Jun Yu, Paul B Lai, Ka F To, Joseph J Y Sung.   

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. It is more prevalent in men than women. Related to this, recent genetic studies have revealed a causal role for androgen receptor (AR) in hepatocarcinogenesis, but the underlying molecular mechanism remains unclear. Here, we used genome-wide location and functional analyses to identify a critical mediator of AR signaling - cell cycle-related kinase (CCRK) - that drives hepatocarcinogenesis via a signaling pathway dependent on β-catenin and T cell factor (TCF). Ligand-bound AR activated CCRK transcription and protein expression via direct binding to the androgen-responsive element of the CCRK promoter in human HCC cell lines. In vitro analyses showed that CCRK was critical in human cell lines for AR-induced cell cycle progression, hepatocellular proliferation, and malignant transformation. Ectopic expression of CCRK in immortalized human liver cells activated β-catenin/TCF signaling to stimulate cell cycle progression and to induce tumor formation, as shown in both xenograft and orthotopic models. Conversely, knockdown of CCRK decreased HCC cell growth, and this could be rescued by constitutively active β-catenin or TCF. In primary human HCC tissue samples, AR, CCRK, and β-catenin were concordantly overexpressed in the tumor cells. Furthermore, CCRK overexpression correlated with the tumor staging and poor overall survival of patients. Our results reveal a direct AR transcriptional target, CCRK, that promotes hepatocarcinogenesis through the upregulation of β-catenin/TCF signaling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21747169      PMCID: PMC3148736          DOI: 10.1172/JCI45967

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  66 in total

1.  Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis.

Authors:  Woo Sung Moon; Ho Sung Park; Ki Hoon Yu; Min Young Park; Kyung Ryoul Kim; Kyu Yun Jang; Jong Suk Kim; Baik Hwan Cho
Journal:  Hum Pathol       Date:  2006-07-27       Impact factor: 3.466

2.  Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.

Authors:  J Zucman-Rossi; S Benhamouche; C Godard; S Boyault; G Grimber; C Balabaud; A S Cunha; P Bioulac-Sage; C Perret
Journal:  Oncogene       Date:  2006-09-11       Impact factor: 9.867

3.  Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters.

Authors:  Alfred S L Cheng; Victor X Jin; Meiyun Fan; Laura T Smith; Sandya Liyanarachchi; Pearlly S Yan; Yu-Wei Leu; Michael W Y Chan; Christoph Plass; Kenneth P Nephew; Ramana V Davuluri; Tim H-M Huang
Journal:  Mol Cell       Date:  2006-02-03       Impact factor: 17.970

Review 4.  Mining the Wnt pathway for cancer therapeutics.

Authors:  Nick Barker; Hans Clevers
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

5.  PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib.

Authors:  Shu-Ichi Ueda; Yuji Basaki; Masumi Yoshie; Katsuhiro Ogawa; Shotaro Sakisaka; Michihiko Kuwano; Mayumi Ono
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

Review 6.  Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?

Authors:  David J Mulholland; Shoukat Dedhar; Gerhard A Coetzee; Colleen C Nelson
Journal:  Endocr Rev       Date:  2005-08-26       Impact factor: 19.871

7.  Genome-wide functional analysis of human cell-cycle regulators.

Authors:  Mridul Mukherji; Russell Bell; Lubica Supekova; Yan Wang; Anthony P Orth; Serge Batalov; Loren Miraglia; Dieter Huesken; Joerg Lange; Christopher Martin; Sudhir Sahasrabudhe; Mischa Reinhardt; Francois Natt; Jonathan Hall; Craig Mickanin; Mark Labow; Sumit K Chanda; Charles Y Cho; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-25       Impact factor: 11.205

8.  The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription.

Authors:  Delphine Cougot; Yuanfei Wu; Stefano Cairo; Julie Caramel; Claire-Angélique Renard; Laurence Lévy; Marie Annick Buendia; Christine Neuveut
Journal:  J Biol Chem       Date:  2006-12-11       Impact factor: 5.157

9.  Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma.

Authors:  Shiou-Hwei Yeh; Chi-Ming Chiu; Chi-Ling Chen; Shu-Fen Lu; Hey-Chi Hsu; Ding-Shinn Chen; Pei-Jer Chen
Journal:  Int J Cancer       Date:  2007-04-15       Impact factor: 7.396

10.  The cyclin-dependent kinase (CDK) family member PNQALRE/CCRK supports cell proliferation but has no intrinsic CDK-activating kinase (CAK) activity.

Authors:  Lara Wohlbold; Stéphane Larochelle; Jack C-F Liao; Geulah Livshits; Juliet Singer; Kevan M Shokat; Robert P Fisher
Journal:  Cell Cycle       Date:  2006-03-01       Impact factor: 4.534

View more
  51 in total

1.  Functional genomics identifies drivers of medulloblastoma dissemination.

Authors:  Michael Mumert; Adrian Dubuc; Xiaochong Wu; Paul A Northcott; Steven S Chin; Carolyn A Pedone; Michael D Taylor; Daniel W Fults
Journal:  Cancer Res       Date:  2012-08-08       Impact factor: 12.701

2.  Cell cycle-related kinase links androgen receptor and β-catenin signaling in hepatocellular carcinoma: why are men at a loss?

Authors:  Prince K Awuah; Satdarshan P Monga
Journal:  Hepatology       Date:  2012-03       Impact factor: 17.425

3.  Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor.

Authors:  Yun Teng; Lacey M Litchfield; Margarita M Ivanova; Russell A Prough; Barbara J Clark; Carolyn M Klinge
Journal:  Mol Cell Endocrinol       Date:  2014-05-17       Impact factor: 4.102

4.  General transcription factor IIb overexpression and a potential link to proliferation in human hepatocellular carcinoma.

Authors:  Liren Li; Aixian Zhang; Xiaolei Cao; Jing Chen; Yunfei Xia; Hui Zhao; Aiguo Shen
Journal:  Pathol Oncol Res       Date:  2012-10-05       Impact factor: 3.201

5.  CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.

Authors:  Q Wang; J Ma; Y Lu; S Zhang; J Huang; J Chen; J-X Bei; K Yang; G Wu; K Huang; J Chen; S Xu
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

6.  The direct effect of estrogen on cell viability and apoptosis in human gastric cancer cells.

Authors:  Jian Qin; Min Liu; Qianshan Ding; Xiang Ji; Yarong Hao; Xiaomin Wu; Jie Xiong
Journal:  Mol Cell Biochem       Date:  2014-06-17       Impact factor: 3.396

7.  USP22 regulates oncogenic signaling pathways to drive lethal cancer progression.

Authors:  Randy S Schrecengost; Jeffry L Dean; Jonathan F Goodwin; Matthew J Schiewer; Mark W Urban; Timothy J Stanek; Robyn T Sussman; Jessica L Hicks; Ruth C Birbe; Rossitza A Draganova-Tacheva; Tapio Visakorpi; Angelo M DeMarzo; Steven B McMahon; Karen E Knudsen
Journal:  Cancer Res       Date:  2013-11-06       Impact factor: 12.701

8.  Cell cycle-related kinase in carcinogenesis.

Authors:  Ye Tian; Han Wan; Guang Tan
Journal:  Oncol Lett       Date:  2012-07-27       Impact factor: 2.967

9.  Epigenetic silencing of GDF1 disrupts SMAD signaling to reinforce gastric cancer development.

Authors:  W Yang; M T S Mok; M S M Li; W Kang; H Wang; A W Chan; J-L Chou; J Chen; E K W Ng; K-F To; J Yu; M W Y Chan; F K L Chan; J J Y Sung; A S L Cheng
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

Review 10.  Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.

Authors:  Wen-Lung Ma; Hsueh-Chou Lai; Shuyuan Yeh; Xiujun Cai; Chawnshang Chang
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.